Introduction
Hepatocellular carcinoma (HCC) is a common human malignancy with an extremely poor prognosis.
1,2 Gene therapy represents a promising treatment for HCC. Among the potential suicide-gene therapies for cancer, the herpes simplex virus (HSV)-thymidine kinase (TK)/ ganciclovir (GCV) system has been widely investigated. [3] [4] [5] HSV-TK converts the nontoxic agent GCV into a highly toxic phosphorylated GCV, which acts as a chain terminator of DNA synthesis and an inhibitor of DNA polymerase. [6] [7] [8] It is not yet possible to transduce therapeutic genes into all of the target tumor cells. However, one considerable advantage of the HSV-TK system is the 'bystander effect', in which HSV-TKnegative tumor cells are destroyed as a result of their proximity to any HSV-TK-positive tumor cells that have been exposed to phosphorylated GCV. 9 The tumorspecific activation of the therapeutic gene is crucial in order to minimize the side effects of treatment, and suicide-gene therapy controlled by the a-fetoprotein (AFP) promoter has proved satisfactory in this respect in both in vitro and in vivo models. [10] [11] [12] [13] [14] However, the level of AFP expression varies among cases, and nonmalignant tissue -particularly, chronic inflammatory tissue -can also express AFP. 2, 15 In order to overcome the difficulties of tumor-specific activation, radiation-inducible promoters can provide spatial control of irradiation, and might therefore be useful in the treatment of hepatomas. 16 We previously reported a novel technique for hepatoma-specific suicide-gene therapy, using a radio-inducible early-growth response-1 (Egr-1)-promoter containing six CArG boxes corresponding to the radiosensitive and serum-responsive elements. 17 The Egr-1 gene was preferentially expressed in hepatoma cells compared with the surrounding nontumor tissue, and its promoter was significantly activated after radiation exposure. However, this approach might not be suitable for multiple hepatomas, because whole-liver irradiation could be fatal to patients: firstly, as a result of direct injury from irradiation, which produces free radicals that cause DNA-strand breaks; and secondly, through the nonspecific activation of suicide genes. Recently, the Egr-1 promoter was shown to be activated not only by external radiation but also by internal radiation from isotopes such as Tc-99m, Ga-67 and I-131. 18 Importantly, I-131-labelled lipiodol (I-131-Lip) concentrates preferentially within hepatomas, where it is retained for significantly longer periods than in non-neoplastic tissues. [19] [20] [21] [22] In addition, I-131 generates 606-MeV b-rays that produce a strong effect over short distances, which could therefore enhance the bystander effect through increased intracellular communication. 23 In the present study, we investigated whether combined therapy comprising transduction of the EgrTK gene and internal radiation with I-131 was able to reduce tumor development in HCC.
Results
Biodistribution of I-131-Lip in tumor-bearing mice analyzed using autoradiography after injection into the tumor xenograft Autoradiography was carried out after I-131-Lip injection in order to examine whether I-131-Lip accumulated preferentially in the tumor. These mice did not receive iodide-uptake inhibitors such as NaI. As shown in Figure  1 , I-131-Lip accumulated preferentially at the tumor site and remained there for up to 7 days, which is consistent with the observed physiological half-life of I-131. In contrast, no I-131-Lip accumulation was detected in any other organs, including the thyroid and gut. A densitometric analysis using Bio-imaging Analyzer System (BAS5000, Fuji) showed the diphasic accumulation of radioisotopes.
Softex roentgenograms revealed the iodide uptake, which was visualized as white dots, only in tumors treated with I-131-Lip. No accumulation in any other organs was observed (data not shown).
Egr-1-promoter activity in vivo
An in vivo luciferase assay was performed to examine whether the Egr-1 promoter could be activated by I-131-Lip in tumor xenografts. EgrLuc-HVJ-liposome was introduced into tumors when they reached 8-10 mm in size, along with 0-20 mCi of I-131-Lip, which was injected at 16 h post-transfection. The tumor tissue specimens were excised and examined to determine their luciferase activity 40 h after transfection. Radiation-induced promoter activity was expressed as relative light units, after correction using nonirradiated cell lines. The differences in transfection efficiencies between tumors were negligible. Internal radiation therapy using I-131-Lip significantly increased the Egr-1-promoter activity in the hepatoma tissue specimens (4.4-fold at 2 mCi and 28.8-fold at 20 mCi), whereas no increase was observed in the normal liver and lung tissue specimens (Figure 2 ).
Egr-1 protein expression in tumor tissue after I-131-Lip treatment
Egr-1 immunohistochemistry was carried out in tumors after treatment in order to examine the level of Egr-1 gene expression. Faint staining was detected in the tumor cell clusters of untreated hepatoma tissue ( Figure  3a ), but not in the absence of the primary antibody (Figure 3b ). In contrast, a significant degree of Egr-1 activation was observed in the tissue specimens treated with I-131-Lip (Figure 3c ). These results clearly show that Egr-1 gene expression can be induced by internal irradiation using I-131, as well as by external radiation exposure.
In vivo EgrTK/GCV treatment of tumor xenografts in mice
The whole-body effective half-life of the therapeutic activity, which was measured daily using a radiationsurvey meter, showed an exponential decrease with a mean of 8 days (data not shown). To further investigate Figure 2 Egr-1-promoter activity in vivo. Egr-1-promoter activity was significantly increased by internal irradiation to tumors that were transfected with the Egr-Luc gene. However, no increase in the activity was detected in either the liver or lung tissue specimens. *Po0.05, **Po0.01 versus control groups. In contrast, the EgrTK-transfected animals (n ¼ 8) that received irradiation without GCV exhibited no suppression of the tumor volume compared to the untreated animals (n ¼ 10). A retardation of tumor growth was seen in the EgrTK-transfected group that received GCV without irradiation (n ¼ 8). Complete tumor regression was observed in all the EgrTK-transfected tumors that received I-131-Lip and GCV from 24 days to 42 days after gene therapy ( Figure 4b ). Thereafter, seven of eight tumors continued to show regression at 80 days post gene therapy, although one remaining tumor slowly regrew.
Serum AFP measurement
AFP is commonly used as a diagnostic marker for HCC because of its high sensitivity, and human Huh7 cells produce human AFP. Therefore, in order to estimate the viable volume of implanted hepatoma tumors, the serum AFP levels were measured at the time points indicated in Figure 5 . The serum AFP values progressively increased in the untreated controls, whereas a strong suppression was observed in the EgrTK plus I-131-Lip group, and these findings were consistent with those from the in vivo gene-therapy data.
Histological findings
Hematoxylin-eosin staining revealed massive apoptotic and partially necrotic cells with intratumoral lymphocyte-infiltration lesions in the EgrTK/GCV plus I-131-Lip group (Figure 6d ) compared to the untreated tumor (Figure 6a ). In contrast, slight tumor cell damage with necrosis, but without any inflammatory cell infiltration, was observed in the I-131-Lip-injected group (Figure 6c ).
EgrTK/GCV treatment resulted in an increased number of apoptotic tumor cells, but it did not cause any necrotic tumor tissue damage (Figure 6b ). 
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Discussion
The lymphographic agent lipiodol (also known as iodized oil) has been shown to specifically localize and persist within hepatoma tissue. [24] [25] [26] [27] Although lipiodol itself does not seem to have any significant anticancer effects, it allows anticancer drugs to be delivered selectively to tumor tissue when applied as an emulsion. 28 Lipiodol contains sterile iodine 127, so the labelling of lipiodol with radioactive I-131 can be achieved through a simple radioisotopic exchange method. 29 The therapeutic effectiveness is primarily limited to areas in which lipiodol accumulates, as I-131 generates 606-MeV b-rays that produce strong effects over distances of less than 2.0 mm. 30 These findings indicate that I-131-Lip has potential advantages for use in hepatoma therapy. [31] [32] [33] The selective delivery and retention of lipiodol are thought to result from the developed neovasculature, enhanced permeability and the poor reticuloendothelial systems observed in hepatoma tissues. Despite this capacity for the selective accumulation at the tumor site, clinical studies have shown the effectiveness of such I-131-Lip therapy alone to only be temporary, and early HCC recurrence was observed in many cases. In contrast, recent reports have shown that I-131 therapy following a curative resection significantly improved both the disease-free interval and the survival rates. 22, 34 Furthermore, no significant side effects -such as liver toxicity, renal disorders, bone-marrow suppression, thyroid dysfunction or respiratory dysfunction -have been reported after I-131-Lip administration.
We previously reported that a total dose of 20 Gy of external ionizing radiation could selectively and effectively activate the Egr-1 promoter, thus resulting in tumor regression. 17 However, it is not possible to focus specifically on multiple tumor lesions, even when using conformal irradiation. Furthermore, high doses (50 Gy or above) of whole-liver irradiation are known to be toxic to normal livers, 15 and livers with hepatitis or cirrhosis are thought to be even more highly radiosensitive. These factors have clear implications regarding the treatment of HCC.
A recent report demonstrated that the Egr-1 promoter can be activated by both external and internal radiation, which thus prompted our investigation of I-131-Lip as both an antitumor agent and a molecular switch for radio-inducible promoter Egr-1-based gene therapy. Our results revealed a 28. Many different genes can be activated after irradiation, including c-fos, c-jun, TNF-a and NF-kB. However, the advantage of the Egr-1 promoter is that it is tightly regulated by irradiation and its basal activity is relatively low in nonirradiated tumors. Indeed, our in vivo luciferase assay data showed the leakage of the transduced suicide gene to be extremely low, thus suggesting that I-131-Lip could efficiently regulate therapeutic gene expression. Although, we have not examined whether restimulation of the Egr-1 promoter is possible after multiple treatments with internal radiation, our in vivo gene-therapy data suggested that HSV-TK gene expression might be prolonged. We have previously shown that the Egr-1 promoter was relatively hepatoma tissue specific. 17 More interestingly, the Egr-1 gene has recently been shown to be overexpressed in prostate cancer and to be closely associated with its carcinogenesis. 35 Regarding the optimal method for administering I-131-Lip to patients, arterial chemoembolization is generally performed to treat multiple HCC. However, repeated embolization is limited by ischemic damage to normal livers and/or occlusion of the main feeding artery. Importantly, I-131-Lip therapy without embolization can be repeated in patients with hepatoma, thus making internal radiation-controlled suicide-gene therapy suitable for use even in regions of tumor recurrence.
Regarding future human clinical trials, a subcutaneous HCC implantation model may not be an ideal situation. If adequate animal models are developed, further studies will be necessary to establish an adequate treatment method for intrahepatic tumors with this strategy with an ultimate goal of future clinical application.
Up to now, adenoviruses have proven to be the most efficient gene-transfer vectors. However, the clinical findings from gene therapies using these vectors directed at the liver have also revealed fatal side effects that occur as a result of systemic inflammatory responses. 36 Safer gene-transfer methods, such as nonviral vectors, must therefore be considered for liver-related gene therapy. In the present study, we used an HVJ-liposome vector for the transfer of genes, which proved to be efficient, safe and simple to use in vivo. This vector was constructed from inactivated HVJ envelope proteins and anionic liposomes. It therefore had a low immunogenicity, which allowed for repeated administrations without any significant tissue damage. [37] [38] [39] The gene-transfer efficiency might thus be further improved by using other lipid formations or cointroduced proteins. Single applications of HVJ-liposome-mediated gene transfer are transient, as the transferred gene remains episomal in the nucleus, similar to adenoviruses and other physical methods. However, repeated gene transfer might result in a long-term gene expression. Moreover, previous studies have detected no obvious functional or histological liver damage after gene transfer using the HVJliposome vector. 39 These preliminary results suggest that the HVJ-liposome method has several advantages compared with other gene-delivery systems for the in situ transduction of cancer cells, even though the vector itself does not have any specificity for tumor cells.
In conclusion, radio-inducible suicide-gene therapy in combination with I-131-Lip treatment was found to enhance the efficacy of gene therapy for hepatomas. This approach might therefore represent a potentially effective treatment modality for clinically unresectable multiple HCC.
Materials and methods
Plasmid construction
EgrLuc and EgrTK plasmids were constructed according to the method reported previously. 17 Briefly, a region of the murine Egr-1 promoter (À425 to +0) was amplified using the polymerase chain reaction with specific primers from the pE425 plasmid, 40 under the kind guidance of Dr DW Kufe of the Dana-Farber Cancer Institute, Harvard Medical School, USA. The polymerase chain reaction fragment was inserted upstream of firefly luciferase or the HSV-TK gene, producing the EgrLuc or EgrTK plasmid, respectively.
Cell lines
The human hepatoma cell line Huh7, which was kindly provided by Dr H Nakabayashi of the Department of Biochemistry, Hokkaido University School of Medicine, Japan, was cultured in RPMI 1640 medium (Gibco, Long Island, NY, USA) supplemented with 5% fetal bovine serum, 100 U/ml penicillin and 100 mg/ml streptomycin.
Preparation of the HVJ-liposome vector
The HVJ-liposome vector was prepared according to the method described previously. Briefly, phosphatidylserine, phosphatidylcholine and cholesterol were mixed at a weight ratio of 1:4.8:2. The lipid mixture (10 mg) was dried by the removal of chloroform, and then hydrated in 200 ml balanced salt solution containing DNA-highmobility group I complex (200:64 mg), which had been incubated previously at 201C for 1 h. Liposomes were prepared by shaking and sonication. The liposome suspension (10 mg lipids) was mixed with HVJ (30 000 HAU) in a total volume of 1 ml balanced salt solution. The mixture was incubated at 41C for 10 min, and then for 1 h with shaking at 371C. Free HVJ was removed from the HVJ-liposome solution using sucrose density gradient centrifugation, and the second layer of sucrose containing the HVJ-liposome vector was collected.
Labelling of lipiodol with I-131
I-131-labelled lipiodol, which was produced by replacing the iodine residue of lipiodol with I-131-C104 under aseptic conditions, was supplied by The First Radioisotope Co. Ltd (Tokyo, Japan). The labelling index was consistently more than 99% and the radioactivity of the I-131-labelled lipiodol was 131 MBq/ml.
In vivo luciferase assay
To correct for transfection efficiencies, the cytomegalovirus-renilla (sea pansy) luciferase vector was cotransfected in each experiment. EgrLuc (196 mg) and cytomegalovirus-Luc (4 mg) plasmids were encapsulated in the HVJ-liposome and transfected into established tumors in nude mice. Based on the findings of previous reports, we administered 2-20 mCi of I-131-labelled Suicide-gene therapy for HCC Y Kawashita et al lipiodol to each animal in a total volume of 100 ml, diluted with cold lipiodol 24 h after transfection. 41 Subsequently, 48 and 72 h after transfection, the tumors, livers and lungs of the animals were excised and immersed in 1200 ml of 3 Â reporter lysis buffer, and then were cut with sterile scissors. The mixture was transferred to a 15 ml falcon tube and homogenized using a sonicator for 5-10 min, followed by centrifugation at 3000 r.p.m. for 5 min. The supernatant was then transferred into a 1.5 ml Eppendorf tube. Aliquots were assayed for luciferase activity in a Lumat LB9501 luminometer (Berthold Systems, Aliquippa, PA, USA) using 20 ml of supernatant and 100 ml of reconstituted luciferase-assay reagent (Promega, Madison, WI, USA). The light units produced were measured for 20 s, 3-5 min after mixing. The reagents used in this step were obtained from the Dual-Luciferase s Reporter Assay System (Promega).
In vivo imaging and quantitation of accumulated radionuclides in tumor xenografts in Balb/c nu/nu mice Autoradiography was carried out in order to visualize I-131 accumulation in the tumors. The mice were placed under general anesthesia by the intraperitoneal injection of a sterile 2.5% solution of 2-2-2-tribromoethanol (Aldrich chemicals, Milwaukee, WI, USA). The anaesthetized animals were then placed on an imaging plate (Fuji, Tokyo, Japan) in a supine position in a dark room for 5 min, followed by a densitometric analysis using a Fujix Bioimaging Analyzer BAS2000 (Fuji).
An in vivo imaging study was also performed in order to examine the distribution of I-131 in established tumors in nude mice. After 3-5 weeks, when the tumor diameter had reached 8-10 mm, 200 ml of EgrLuc-HVJ-liposome solution was injected into the tumor.
In vivo gene therapy
Female nude mice (Charles-River Japan, Tokyo, Japan) aged 4-6 weeks were injected subcutaneously on both flanks with 200 ml of an Huh7 cell suspension (1 Â 10 7 cells) in PBS. A transduction efficiency to the subcutaneous tumor of more than 50% was attained using the HVJ-liposome method, as reported previously. 17 After 3-5 weeks, when the tumor diameter had reached 8-10 mm, 200 ml of the EgrTK-HVJ-liposome was injected (on days 1 and 8). For the in vivo luciferase assay experiments, 0-20 mCi I-131-lipiodol was injected into the tumor xenografts on day 2. The doses were selected on the basis of the clinical data and our pilot study. GCV administration (20 mg/kg per day injected intraperitoneally) was initiated 3 h after transfection and then continued for 2 weeks.
The mice were divided into four groups as follows: untreated animals (Group A; n ¼ 10); those receiving EgrTK-vector transfection and irradiation (Group B; n ¼ 8); those receiving EgrTK-vector transfection and GCV (Group C; n ¼ 8) and those receiving EgrTK-vector transfection, irradiation and GCV (Group D; n ¼ 8). None of the mice showed signs of wasting or any other indications of toxicity. The tumor volume was calculated using the formula 1/2 Â (ab 2 ), where 'a' represents the longer diameter and 'b' represents the shorter diameter. The care and treatment of the animals were in accordance with the guidelines of the Nagasaki University Institutional Ethics Committee, Japan.
Measurement of serum AFP
In parallel with the measurement of tumor size, blood samples were collected from representative mice at various intervals by retro-orbital bleeding. Serum AFP levels were analyzed using a radioimmunoassay. 42 
Hematoxylin-eosin staining
To evaluate the mechanism causing the synergistic effects of HSV-TK gene therapy and internal radiation by I-131-Lip, samples of subcutaneous tumors were carefully dissected and removed at various intervals during therapy. The tumor tissues were fixed with 10% neutral formalin, embedded in paraffin and histologically examined.
Egr-1 immunohistochemistry
Immunohistochemical testing was performed in the hepatoma xenografts in order to evaluate the activation of the Egr-1 gene after internal radiation. The samples were fixed with 4% paraformaldehyde and embedded in paraffin. The tissues were then cut into 3 mm sections, deparaffinized in xylene and rehydrated. The sections were preincubated with normal bovine serum to prevent nonspecific binding, and then were incubated overnight at 41C with an optimal dilution (5 mg/ml) of the primary mouse monoclonal antibody against human Egr-1 (Oncogene Science, Uniondale, NY, USA). The slides were sequentially incubated with the secondary antibody and the reaction products were visualized by DAB using a SIMPLE STAIN MAX-PO (MULTI) kit (Nichirei, Tokyo, Japan). Negative control samples were prepared by replacing the primary antibody with nonimmune murine serum.
Statistical analysis
All data are presented as the mean7standard deviation. Statistical analyses were performed using the Mann-Whitney U-test. Probability (P) values o0.05 were considered to be statistically significant.
